< Back to search
Filter
1

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT07456605

Phase1, Recruiting

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

for
Multiple Myeloma, Refractory Multiple Myeloma,
Location: Boston MA
Sponsor: David Avigan

Sex: All

Age: 18+

Code: NCT07377435

Phase1, Recruiting

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

for
Relapsed Refractory Multiple Myeloma (RRMM)
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT07032714

Phase1, Recruiting

ELISA in Relapsed/Refractory MM

for
Relapsed Refractory Multiple Myeloma (RRMM),
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT06832865

Phase2, Recruiting

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

for
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin

Sex: All

Age: 18+

Code: NCT07093554

Phase1, Recruiting

Interested in new relapsing multiple sclerosis trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Plan Development for Giving Teclistamab in the Outpatient Setting

for
Multiple Myeloma, Relapsed Cancer, Refractory Cancer
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT06251076

Recruiting

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

for
Multiple Myeloma Refractory, Relapsed Multiple Myeloma
Location: Quebec, Levis
Sponsor: CHU de Quebec-Universite Laval

Sex: All

Age: 18+

Code: NCT07094048

Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

for
Relapsed or Refractory Multiple Myeloma
Location: Boston MA, New York NY, Philadelphia PA, Charlotte NC,
Sponsor: ModernaTX, Inc.

Sex: All

Age: 18+

Code: NCT07116616

Phase1, Phase2, Recruiting

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

for
Multiple Myeloma, Multiple Myeloma in Relapse,
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT07200089

Phase1, Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

for
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Location: Madison WI
Sponsor: Natalie Callander

Sex: All

Age: 18+

Code: NCT07479979

Phase1, Phase2, Recruiting

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma, Relapse Multiple Myeloma,
Location: Boston MA
Sponsor: David Avigan

Sex: All

Age: 18+

Code: NCT06799026

Phase1, Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Boston MA, Hackensack NJ, New Brunswick NJ,
Sponsor: CellCentric Ltd.

Sex: All

Age: 18+

Code: NCT07096778

Phase2, Recruiting

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Location: New York NY, Columbus OH, Atlanta GA, Houston TX
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07222761

Phase3, Recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma, Refractory Multiple Myeloma,
Location: San Francisco CA
Sponsor: Alfred Chung, MD

Sex: All

Age: 18+

Code: NCT06348108

Phase1, Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

for
Relapsed/Refractory Multiple Myeloma
Location: New York NY, Hackensack NJ, Miami FL, Toronto,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT04973605

Phase1, Phase2, Recruiting

Host Dendritic Cells in Allograft Patients

for
Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease,
Location: New York NY
Sponsor: Icahn School of Medicine at Mount Sinai

Sex: All

Age: 18 - 70

Code: NCT00935597

Phase1, Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Relapsed and/or Refractory Multiple Myeloma
Location: Boston MA, New Haven CT, New York NY, Tampa FL,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06153251

Phase1, Recruiting

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

for
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Location: Boston MA, Rochester NY, Chapel Hill NC, Detroit MI,
Sponsor: Opna Bio LLC

Sex: All

Age: 18+

Code: NCT06433947

Phase1, Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

for
NHL, Multiple Myeloma, Blood Cancer,
Location: Providence RI, Fairfax VA, Winston-Salem NC,
Sponsor: Indapta Therapeutics, INC.

Sex: All

Age: 18+

Code: NCT06119685

Phase1, Phase2, Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

for
Relapsed or Refractory Multiple Myeloma
Location: Boston MA, Shirley NY, Farmington CT, Lake Success NY,
Sponsor: Celgene

Sex: All

Age: 18+

Code: NCT05519085

Phase3, Recruiting